These findings elucidate the molecular basis for GMSC‐EVs tropism to arthritic lesions and establish CCR2 as a pivotal target for developing precision‐engineered EVs therapies with enhanced specificity for RA treatment. The gene discussed is CCR2; the disease is rheumatoid arthritis.